Aan Het Rot M, Collins Ka, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ (2010) Safety and efficacy of repeated- dose intravenous ketamine for treatment-resistant depres- sion. Biol Psychiatry 67:139–145.

Aan Het Rot M, Zarate Ca, Charney DS, Mathew SJ (2012) Keta- mine for depression: where do we go from here?

Biol Psychiatry 72:537–547.

Aitken RC (1969) Measurement of feelings using visual analog scales. Proc R Soc Med 62:989.

Argiriadou H, Himmelseher S, Papagiannopoulou P, Georgiou M, Kanakoudis F, Giala M, Kochs E (2004) Improvement of pain treatment after major abdominal surgery by intravenous S+- ketamine. Anesth Analg 98:1413–1418, table of contents.

Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng P-f, Kava- lali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioral antidepressant responses. Nature 475:91–95.

Berman RM, Cappiello a, Anand a, Oren Da, Heninger GR, Char- ney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354.

Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM (1998) Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS). J Trauma Stress 11:125–136.

Brittner M, Micoulaud-Franchi JA, Richieri R, Boyer L, Adida M, Lancon C, Fond G (2014) [Ketamine in acute and severe major depressive disorder]. Presse Med 43:492–500.

Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK (2014) Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmacol 4:75–99.

Chong C, Schug SA, Page-Sharp M, Jenkins B, Ilett KF (2009) Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: preliminary  findings from a three-way randomized, crossover study. Clin Drug Investig 29:317–324.

Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Sal- vadore G, Machado-Vieira R, Manji HK, Zarate CA Jr (2010a) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:793–802.

DiazGranados N, Ibrahim La, Brutsche NE, Ameli R, Henter ID, Luckenbaugh Da, Machado-Vieira R, Zarate Ca (2010b) Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 71:1605–1611.

Ghasemi M, Kazemi MH, Yoose  A, Ghasemi A, Paragomi P, Amini H, Afzali MH (2014) Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy

Xu et al. | 15

 in hospitalized patients with major depressive disorder. Psychiatry Res 215:355–361.

Hamilton M (1960) Rating scale for depression. J Neurol Neurosur PS 23:56–62.

Higgins JPT, Green S (editors) (2009) Cochrane handbook for systematic reviews of interventions version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from

Katalinic N, Lai R, Somogyi A, Mitchell PB, Glue P, Loo CK (2013) Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Aust N Z J Psychiatry 47:710– 727.

Kudoh A, Takahira Y, Katagai H, Takazawa T (2002) Small-dose ketamine improves the postoperative state of depressed patients. 114–118.

Lai R, Katalinic N, Glue P, Somogyi AA, Mitchell PB, Leyden J, Harper S, Loo CK (2014) Pilot dose-response trial of i.v. ketamine in treatment-resistant depression. World J Biol Psychiatry 0:1–6.

Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, Feder A, Iosifescu DV, Charney DS, Murrough JW (2014) A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 76:970–976.

Larkin GL, Beautrais AL (2011) A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 14:1127–1131.

Martinowich K, Jimenez DV, Zarate CA, Manji HK (2013) Rapid antidepressant effects: moving right along. Mol Psychiatry 18:856–863.

McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW (2014) A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychological Medicine FirstView:1–12.

Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382– 389.

Murrough J, Soleimani L, DeWilde K, Collins K, Lapidus K, Iaco- viello B, Lener M, Kautz M, Kim J, Stern J (2015) Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychological medicine 1–10.

Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ (2013) Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170:1134–1142.

Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799–812.

Paul R, Schaaff N, Padberg F, Möller H-J, Frodl T (2009) Comparison of racemic ketamine and S-ketamine in treatment-

resistant major depression: report of two cases. World J Biol Psychiatry 10:241–244.

Price RB, Nock MK, Charney DS, Mathew SJ (2009) Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66:522–526.

Rasmussen KG, Lineberry TW, Galardy CW, Kung S, Lapid MI, Palmer BA, Ritter MJ, Schak KM, Sola CL, Hanson AJ, Frye MA (2013) Serial infusions of low-dose ketamine for major depression. J Psychopharmacol 27:444–450.

RevMan (2014) The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, Flood P, Simpson HB (2013) Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology 38:2475–2483.

Senn S (2002) Crossover trials in clinical research: John Wiley & Sons.

Shiroma PR, Johns B, Kuskowski M, Wels J, Thuras P, Albott CS, Lim KO (2014) Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment-resistant depression. J Affect Disord 155:123–129.

Sos P, Klirova M, Novak T, Kohutova B, Horacek J, Palenicek T (2013) Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett 34:287–293.

Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH, Sanacora G The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. Psychiatry Res. 2011 February 28; 191(2): 122–127.

Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T (2015) The global burden of mental, neurological and substance use disorders: an analysis from the global burden of disease study 2010. PLoS ONE 10:e0116820.

Young R, Biggs J, Ziegler V, Meyer D (1978) A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 133:429–435. Zarate CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgrana- dos N, Cravchik A, Selter J, Marquardt Ca, Liberty V, Luckenbaugh Da (2012) Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71:939–946.

Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Lucken-baugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864.

Zarate CA Jr, Brutsche N, Laje G, Luckenbaugh DA, Venkata SLV, Ramamoorthy A, Moaddel R, Wainer IW (2012) Relationship of ketamine’s plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry 72:331–338. References BDNF


1. McGuffin P: Affective disorders. In Essential Psychiatry. Edited by Murray RM, Kendler KS, McGuffin P, Wessely S, Castle D. Cambridge, UK: Cambridge University Press; 2008:250–283.

2. Alloy LB, Abramson LY, Smith JM, Gibb BE, Neeren AM: Role of parenting and maltreatment histories in unipolar and bipolar mood disorders: mediation by cognitive vulnerability to depression. Clin Child Fam Psychol Rev 2006, 9:23–64.

3. Fisher H, Hosang GM: Childhood maltreatment and bipolar disorder: a critical review of the evidence. Mind Brain J Psychiatr 2010, 1:75–85.

4. Hosang GM, Korszun A, Jones L, Jones I, Gray JM, Gunasinghe CM, McGuffin P, Farmer AE: Adverse life event reporting and worst illness episodes in unipolar and bipolar affective disorders: measuring environmental risk for genetic research. Psychol Med 2010, 40:1829–1837.

5. Farmer AE, McGuffin P: Humiliation, loss and other types of life events and difficulties: a comparison of depressed subjects, healthy controlsand their siblings. Psychol Med 2003, 33:1169–1175.

6. Hammen C: Stress and depression. Annu Rev Clin Psychol 2005, 1:293–319. 7. Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE: Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry 2010, 167:509–527.

8. Groves JO: Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry 2007, 12:1079–1088.

9. Stein DJ, Daniels WMU, Savitz J, Harvey BH: Brain-derived neurotrophic factor: the neurotrophin hypothesis of psychopathology. CNS Spectr 2008, 13:945–949.

10. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:617–627.

11. Miklowitz DJ, Johnson SL: The psychopathology and treatment of bipolar disorder. Annu Rev Clin Psychol 2006, 2:199–235.

 Additional file 1: Table S1. Quality assessment of brain-derived neurotrophic factor (BDNF), life stress and depression studies [43,65-71,73-83,85,88,89]. Hosang et al. BMC Medicine 2014, 12:7

12. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1747–1757.

13. Menken M, Munsat TL, Toole JF: The global burden of disease study: implications for neurology. Arch Neurol 2000, 57:418–420.

14. Fisher HL, Cohen-Woods S, Hosang GM, Korszun A, Owen M, Craddock N, Craig IW, Farmer AE, McGuffin P, Uher R: Interaction between specific forms of childhood maltreatment and the serotonin transporter gene (5-HTT) in recurrent depressive disorder. J Affect Disord 2013, 145:136–141.

15. Nanni V, Uher R, Danese A: Childhood maltreatment predictsunfavorable course of illness and treatment outcome in depression: a meta-analysis. Am J Psychiatry 2012, 169:141–151.

16. Scott KM, McLaughlin KA, Smith DA, Ellis PM: Childhood maltreatment and DSM-IV adult mental disorders: comparison of prospective and retrospective findings. Br J Psychiatry 2012, 200:469–475.

17. Widom CS, DuMont K, Czaja SJ: A prospective investigation of major depressive disorder and comorbidity in abused and neglected children grown up. Arch Gen Psychiatry 2007, 64:49–56.

18. Agnafors S, Comasco E, Bladh M, Sydsjo G, Dekeyser L, Oreland L, Svedin CG: Effect of gene, environment and maternal depressive symptoms on pre-adolescence behavior problems - a longitudinal study. Child Adolesc Psychiatry Ment Health 2013, 7:10.

19. Morgan C, Fisher H: Environment and schizophrenia: environmental factors in schizophrenia: childhood trauma-a critical review. Schizophr Bull 2007, 33:3–10.

20. Kessler RC, McLaughlin KA, Green JG, Gruber MJ, Sampson NA, Zaslavsky AM, Aguilar-Gaxiola S, Alhamzawi AO, Alonso J, Angermeyer M, Benjet C, Bromet E, Chatterji S, de Girolamo G, Demyttenaere K, Fayyad J, Florescu S, Gal G, Gureje O, Haro JM, Hu CY, Karam EG, Kawakami N, Lee S, Lépine JP, Ormel J, Posada-Villa J, Sagar R, Tsang A, Ustün TB, et al: Childhood adversities and adult psychopathology in the WHO World Mental Health Surveys. Br J Psychiatry 2010, 197:378–385.

21. Hosang GM, Johnson SL, Kiecolt-Glaser J, Di Gregorio MP, Lambert DR, Bechtel MA, Hearne DW, Herron JB, Glaser R:Gender specific association of child abuse and adult cardiovascular disease in a sample of patients with basal cell carcinoma. Child Abuse Negl 2013, 37:374–379.

22. Scott KM, Von Korff M, Angermeyer MC, Benjet C, Bruffaerts R, de Girolamo G, Haro JM, Lépine JP, Ormel J, Posada-Villa J, Tachimori H, Kessler RC: Association of childhood adversities and early-onset mental disorders with adult-onset chronic physical conditions. Arch Gen Psychiatry 2011, 68:838–844.

23. Ezquiaga E, Ayuso Gutierrez JL, Garcia Lopez A: Psychosocial factors and episode number in depression. J Affect Disord 1987, 12:135–138.

24. Hosang GM, Korszun A, Jones L, Jones I, McGuffin P, Farmer AE: Life-event specificity: bipolar disorder compared with unipolar depression. Br J Psychiatry 2012, 201:458–465.

25. Hosang GM, Uher R, Maughan B, McGuffin P, Farmer AE: The role of loss and danger events in symptom exacerbation in bipolar disorder.

J Psychiatr Res 2012, 46:1584–1589.

26. Brown GW, HarrisTO: Social Origins of Depression. A Study of Psychiatric Disorder in Women. London, UK: Routledge; 1978.

27. Uher R, McGuffin P: The moderation by the serotonin transporter gene of environmental adversity in theaetiology of mental illness: review and methodological analysis. Mol Psychiatry 2008, 13:131–146.

28. Uher R, McGuffin P: The moderation by the serotonin transporter gene of environmental adversity in the etiology of depression: 2009 update. Mol Psychiatry 2010, 15:18–22.

29. Monroe SM, Reid MW: Gene-environment interactions in depression research: genetic polymorphisms and life-stresspolyprocedures. Psychol Sci 2008, 19:947–956.

30. Maciejewski PK, Prigerson HG, Mazure CM: Sex differences in event-related risk for major depression. Psychol Med 2001, 31:593–604.

31. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386–389.

32. Uher R: Forum: The case for gene-environment interactions in psychiatry. Curr Opin Psychiatry 2008, 21:318–321.

33. Moffitt TE, Caspi A, Rutter M: Strategy for investigating interactions between measured genes and measured environments. Arch Gen Psychiatry 2005, 62:473–481.

34. Eley TC, Sugden K, Corsico A, Gregory AM, Sham P, McGuffin P, Plomin R, Craig IW: Gene-environment interaction analysis of serotonin system markers with adolescent depression. Mol Psychiatry 2004, 9:908–915.

35. Surtees PG, Wainwright NW, Willis-Owen SA, Luben R, Day NE, Flint J: Social adversity, the serotonin transporter (5-HTTLPR) polymorphismand major depressive disorder. Biol Psychiatry 2006, 59:224–229.

36. Brown GW, Harris TO: Depression and the serotonin transporter 5-HTTLPR polymorphism: a review and a hypothesis concerning gene-environment interaction. J Affect Disord 2008, 111:1–12.

37. Karg K, Burmeister M, Shedden K, Sen S: The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen Psychiatry 2011, 68:444–454.

38. Brown GW, Ban M, Craig TK, Harris TO, Herbert J, Uher R: Serotonin transporter length polymorphism, childhood maltreatment, and chronic depression: a specific gene-environment interaction. Depress Anxiety 2013, 30:5–13.

39. Uher R, Caspi A, Houts R, Sugden K, Williams B, Poulton R, Moffitt TE: Serotonin transporter gene moderates childhood maltreatment’s effects on persistent but not single-episode depression: replications and implications for resolving inconsistent results. J Affect Disord 2011, 135:56–65.

40. Polanczyk G, Caspi A, Williams B, Price TS, Danese A, Sugden K, Uher R, Poulton R, Moffitt TE: Protective effect of CRHR1 gene variants on the development of adult depression following childhood maltreatment: replication and extension. Arch Gen Psychiatry 2009, 66:978–985.

41. Bradley RG, Binder EB, Epstein MP, Tang Y, Nair HP, Liu W, Gillespie CF, Berg T, Evces M, Newport DJ, Stowe ZN, Heim CM, Nemeroff CB, Schwartz A, Cubells JF, Ressler KJ: Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry 2008, 65:190–200.

42. Zimmermann P, Bruckl T, Nocon A, Pfister H, Binder EB, Uhr M, Lieb R, Moffitt TE, Caspi A, Holsboer F, Ising M: Interaction of FKBP5 gene variants and adverse life events in predicting depression onset: results from a 10-year prospective community study. Am J Psychiatry 2011, 168:1107–1116.

43. Kim JM, Stewart R, Kim SW, Yang SJ, Shin IS, Kim YH, Yoon JS: Interactions between life stressors and susceptibility genes (5-HTTLPR and BDNF) on depression in Korean elders. Biol Psychiatry 2007, 62:423–428.

44. Post RM: Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J Psychiatr Res 2007, 41:979–990.

45. Duman RS, Monteggia LM: A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59:1116–1127.

46. Nibuya M, Takahashi M, Russell DS, Duman RS: Repeated stress increases catalytic TrkB mRNA in rat hippocampus. Neurosci Lett 1999, 267:81–84.

47. Roceri M, Cirulli F, Pessina C, Peretto P, Racagni G, Riva MA: Postnatal repeated maternal deprivation produces age-dependent changes of brain-derived neurotrophic factor expression in selected rat brain regions. Biol Psychiatry 2004, 55:708–714.

48. Kauer-Sant’Anna M, Tramontina J, Andreazza AC, Cereser K, da Costa S, Santin A, Yatham LN, Kapczinski F: Traumatic life events in bipolar disorder: impact on BDNF levels and psychopathology. Bipolar Disord 2007, 9:128–135.

49. Grassi-Oliveira R, Stein LM, Lopes RP, Teixeira AL, Bauer ME: Low plasma brain-derived neurotrophic factor and childhood physical neglect are associated with verbal memory impairment in major depression - a preliminary report. Biol Psychiatry 2008, 64:281–285.

50. Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, Elzinga BM: Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry. inpress.

51. Sen S, Duman R, Sanacora G: Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008, 64:527–532.

52. Jiang C, Salton SR: The Role of Neurotrophins in Major Depressive Disorder. Transl Neurosci 2013, 4:46–58.

53. Rybakowski JK: BDNF gene: functional Val66Met polymorphism in mood disorders and schizophrenia. Pharmacogenomics 2008, 9:1589–1593.

54. Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O, Hauser J, Maier W, Kozel D, Henigsberg N, Barreto M, Placentino A, Dernovsek MZ, Schulze TG, Kalember P, Zobel A, Czerski PM, Larsen ER, Souery D, Giovannini C, Gray JM, Lewis CM, Farmer A, Aitchison KJ, McGuffin P, Craig I: Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 2009, 9:225–233.

55. Liu L, Foroud T, Xuei X, Berrettini W, Byerley W, Coryell W, El-Mallakh R, Gershon ES, Kelsoe JR, Lawson WB, MacKinnon DF, McInnis M, McMahon FJ, Murphy DL, Rice J, Scheftner W, Zandi PP, Lohoff FW, Niculescu AB, Meyer ET,

Hosang et al. BMC Medicine 2014, 12:7 Edenberg HJ, Nurnberger JI Jr: Evidence of association between brain-derived neurotrophic factor gene and bipolar disorder. Psychiatr Genet 2008, 18:267–274.

56. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR: The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112:257–269.

57. Jiang X, Xu K, Hoberman J, Tian F, Marko AJ, Waheed JF, Harris CR, Marini AM, Enoch MA, Lipsky RH: BDNF variation and mood disorders: a novel functional promoter polymorphism and Val66Met are associated with anxiety but have opposing effects. Neuropsychopharmacology 2005, 30:1353–1361.

58. Vinberg M, Trajkovska V, Bennike B, Knorr U, Knudsen GM, Kessing LV: The BDNF Val66Met polymorphism: relation to familiar risk of affective disorder, BDNF levelsand salivary cortisol. Psychoneuroendocrinology 2009, 34:1380–1389.

59. Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, Herrera DG, Toth M, Yang C, McEwen BS, Hempstead BL, Lee FS: Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006, 314:140–143.

60. Murakami S, Imbe H, Morikawa Y, Kubo C, Senba E: Chronic stress, as well as acute stress, reduces BDNF mRNA expression in the rat hippocampus but less robustly. Neurosci Res 2005, 53:129–139.

61. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700.

62. Munafo MR, Durrant C, Lewis G, Flint J: Gene X environment interactions at the serotonin transporter locus. Biol Psychiatry 2009, 65:211–219.

63. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N: Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE Statement.

Hum Genet 2009, 125:131–151.

64. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative S: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007, 370:1453–1457.

65. Quinn CR, Dobson-Stone C, Outhred T, Harris A, Kemp AH: The contribution of BDNF and 5-HTT polymorphisms and early life stress to the heterogeneity of major depressive disorder: a preliminary study. Aust N Z J Psychiatry 2012, 46:55–63.

66. Aguilera M, Arias B, Wichers M, Barrantes-Vidal N, Moya J, Villa H, van Os J, Ibanez MI, Ruiperez MA, Ortet G, Fananas L: Early adversity and 5-HTT/BDNF genes: new evidence of gene-environment interactions on depressive symptoms in a general population. Psychol Med 2009, 39:1425–1432.

67. Comasco E, Aslund C, Oreland L, Nilsson KW: Three-way interaction effect of 5-HTTLPR, BDNF Val66Met, and childhood adversity on depression: a replication study. Eur Neuropsychopharmacol 2013, 23:1300–1306.

68. Lavebratt C, Aberg E, Sjoholm LK, Forsell Y: Variations in FKBP5 and BDNF genes are suggestively associated with depression in a Swedish population-based cohort. J Affect Disord 2010, 125:249–255.

69. Chen J, Li X, McGue M: Interacting effect of BDNF Val66Met polymorphism and stressful life events on adolescent depression. Genes Brain Behav 2012, 11:958–965.

70. Grabe HJ, Schwahn C, Mahler J, Appel K, Schulz A, Spitzer C, Fenske K, Barnow S, Freyberger HJ, Teumer A, Petersmann A, Biffar R, Rosskopf D, John U, Völzke H: Genetic epistasis between the brain-derived neurotrophic factor Val66Met polymorphism and the 5-HTT promoter polymorphism moderates the susceptibility to depressive disorders after childhood abuse. Prog Neuropsychopharmacol Biol Psychiatry 2012, 36:264–270.

71. Caldwell W, McInnis OA, McQuaid RJ, Liu G, Stead JD, Anisman H, Hayley S: The role of the Val66Met polymorphism of thebrain derived neurotrophic factor gene in coping strategies relevant to depressive symptoms. PLoS One 2013, 8:e65547.

72. Petryshen TL, Sabeti PC, Aldinger KA, Fry B, Fan JB, Schaffner SF, Waggoner SG, Tahl AR, Sklar P: Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol Psychiatry 2010, 15:810–815.

73. Wichers M, Kenis G, Jacobs N, Mengelers R, Derom C, Vlietinck R, van Os J: symptoms: An attempt at replication. Am J Med Genet B Neuropsychiatry Genet 2008, 147B:120–123.

74. Juhasz G, Dunham JS, McKie S, Thomas E, Downey D, Chase D, Lloyd-Williams K, Toth ZG, Platt H, Mekli K, Payton A, Elliott R, Williams SR, Anderson IM, Deakin JF: The CREB1-BDNF-NTRK2 pathway in depression: multiple gene-cognition- environment interactions. Biol Psychiatry 2011, 69:762–771.

75. Hosang GM, Uher R, Keers R, Cohen-Woods S, Craig I, Korszun A, Perry J, Tozzi F, Muglia P, McGuffin P, Farmer AE: Stressful life events and the brain-derived neurotrophic factor gene in bipolar disorder. J Affect Disord 2010, 125:345–349.

76. Carver CS, Johnson SL, Joormann J, Lemoult J, Cuccaro ML: Childhood adversity interacts separately with 5-HTTLPR and BDNF to predict lifetime depression diagnosis. J Affect Disord 2011, 132:89–93.

77. Perea CS, Paternina AC, Gomez Y, Lattig MC: Negative affectivity moderated by BDNF and stress response. J Affect Disord 2012, 136:767–774.

78. La Greca AM, Lai BS, Joormann J, Auslander BB, Short MA: Children’s risk and resilience following a natural disaster: Genetic vulnerability, posttraumatic stress, and depression. J Affect Disord 2013, 151:860–867.

79. Kaufman J, Yang BZ, Douglas-Palumberi H, Grasso D, Lipschitz D, Houshyar S, Krystal JH, Gelernter J: Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children.

Biol Psychiatry 2006, 59:673–680.

80. Nederhof E, Bouma EM, Oldehinkel AJ, Ormel J: Interaction between childhood adversity, brain-derived neurotrophic factorval/met and serotonin transporter promoter polymorphism on depression: the TRAILS study. Biol Psychiatry 2010, 68:209–212.

81. Elzinga BM, Molendijk ML, Oude Voshaar RC, Bus BA, Prickaerts J, Spinhoven P, Penninx BJ: The impact of childhood abuse and recent stress on serum brain-derived neurotrophic factor and the moderating role of BDNF Val66Met. Psychopharmacology (Berl) 2011, 214:319–328.

82. Bukh JD, Bock C, Vinberg M, Werge T, Gether U, Vedel Kessing L: Interaction between genetic polymorphisms and stressful life events in first episode depression. J Affect Disord 2009, 119:107–115.

83. Herbert J, Ban M, Brown GW, Harris TO, Ogilvie A, Uher R, Craig TK:

Interaction between the BDNF gene Val/66/Met polymorphism and morning cortisol levels as a predictor of depression in adult women. Br J Psychiatry 2012, 201:313–319.

84. Belsky J, Pluess M: Beyond diathesis stress: differential susceptibility to environmental influences. Psychol Bull 2009, 135:885–908.

85. Brown GW, Craig TK, Harris TO, Herbert J, Hodgson K, Tansey KE, Uher R: Functional polymorphism in the Brain-derived neurotrophic factor gene interacts with stressful life events but not childhood maltreatment in the etiology of depression. Depress Anxiety. DOI: 10.1002/da.22221.

86. Power RA, Lecky-Thompson L, Fisher HL, Cohen-Woods S, Hosang GM, Uher R, Powell-Smith G, Keers R, Tropeano M, Korszun A, Jones L, Jones I, Owen MJ, Craddock N, Craig IW, Farmer AE, McGuffin P: The interaction between child maltreatment, adult stressful life events and the 5-HTTLPR in major depression. J Psychiatr Res 2013, 47:1032–1035.

87. Nederhof E, Schmidt MV: Mismatch or cumulative stress: toward an integrated hypothesis of programming effects. Physiol Behav 2012, 106:691–700.

88. Gatt JM, Nemeroff CB, Dobson-Stone C, Paul RH, Bryant RA, Schofield PR, Gordon E, Kemp AH, Williams LM: Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatry 2009, 14:681–695.

89. Jiang R, Brummett BH, Babyak MA, Siegler IC, Williams RB: Brain-derived neurotrophic factor (BDNF) Val66Met and adulthood chronic stress interact to affect depressive symptoms. J Psychiatr Res 2013, 47:233–239.

 The BDNF Val(66)Met x 5-HTTLPR x child adversity interaction and depressive doi:10.1186/1741-7015-12-7

Interaction between stress and the BDNF Val66Met polymorphism in depression: a systematic review and meta-analysis. BMC Medicine 2014 12:7.